Imara M&A

ELVN-002 Clinical Development Strategy Phase 1 TRIAL ● HER2 mutant (e.g., Exon 20 IM) HER2 amplified or overexpressed GOALS ● Demonstrate potential for efficacy at well tolerated dose(s) Identify dose(s) for Phase 1b and beyond Phase 1b / 2 TRIAL ● Late line HER2-mutant NSCLC Explore based on data GOALS ● Earlier lines of therapy Combinations with approved ADCs (e.g., trastuzumab deruxtecan) Establish PoC for HER2-mutant NSCLC Evaluate intracranial activity and combinability with approved ADCs Explore potential beyond NSCLC in other HER2-driven solid tumors (i.e., MBC, CRC, etc.) ADC = Antibody drug conjugate. CRC = Colorectal cancer. MBC = Metastatic breast cancer. NSCLC = Non-small cell lung cancer. PoC = Proof of concept Registrational / Phase 3 TRIAL GOALS ● File on Late line HER2-mutant NSCLC Initial registrational studies HTH against standard of care as mono or combination with HER2 ADC in NSCLC and breast ● Accelerated Approval in late line HER2-mutant NSCLC Initiate registrational studies in early line MBC and HER2-mutant NSCLC 44

View entire presentation